Validierung des neuen CKI spezifischen Inhibitors SK25 in vitro und im orthotopen Xenotransplantationsmodell
Members of the CK I family take place in many regulatory cellular processes. For their membership in signaltransduction pathways, leading to the development of cancer, they’re interesting targets for the development of small molecule inhibitors. We showed that SK 25, a new specific inhibitor of the CK I family, inhibits kinase activity in vitro in a nonomolare range. In vivo, SK25 is able to inhibit cell growth of carcinomatous pancreatic cells in cell culture. In an orthotop transplantation model with SCID mice and BxPc3-tumorcells, we could show that treatment with SK25 has some effects on tumor weight, tumor volume, mitosis, apoptosis (shown in immunohistochemistry) and on expression level of RNA for some relevant gens-loci (shown in realtime PCR). Our results show the high therapeutic potential of small molecules and the chance to develop a clinical therapy.
Erstellung / Fertigstellung
Normierte SchlagwörterAdenocarcinom [GND]
Proteinkinase CK1 [GND]
Casein kinase I [MeSH]